SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithkline Consumer Healthcare inches up on reporting 37% rise in Q2 net profit

09 Nov 2015 Evaluate

GlaxoSmithkline Consumer Healthcare is currently trading at Rs. 5918.70, up by 17.05 points or 0.29% from its previous closing of Rs. 5901.65 on the BSE.

The scrip opened at Rs. 5885.00 and has touched a high and low of Rs. 5945.00 and Rs. 5877.85 respectively.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6564.05 on 15-Apr-2015 and a 52 week low of Rs. 5425.10 on 16-Dec-2014.

Last one week high and low of the scrip stood at Rs. 6023.45 and Rs. 5825.15 respectively. The current market cap of the company is Rs. 24,891.00 crore.

The promoters holding in the company stood at 72.46% while Institutions and Non-Institutions held 12.57% and 14.98% respectively.

The company has reported 36.86% rise in its net profit at Rs 219.37 crore for the quarter ended September 30, 2015 as compared to Rs 160.29 crore for the same quarter in the previous year. The company’s total income has increased by 0.65% to Rs 1183.05 crore for the quarter under review from Rs 1175.46 crore for the corresponding quarter of the previous year.

GlaxoSmithKline Consumer Healthcare is a subsidiary of GlaxoSmithKline plc of UK. GlaxoSmithkline Consumer Healthcare’s core business is manufacturing of health drinks under the brand Horlicks. It exports products to countries like Bangladesh, Myanmar, Sri Lanka, Middle East, Fiji, Mauritius, Nepal, Bhutan and many more.


Glaxo.Cons. Health Share Price

9696.40 0.00 (0.00%)
15-Apr-2020 18:01 View Price Chart
Peers
Company Name CMP
Varun Beverages 461.30
Nestle 1258.55
Britannia Inds 5589.50
LT Foods 419.20
Hatsun Agro Product 939.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×